175 related articles for article (PubMed ID: 37944072)
1. Multiomic Characterization Reveals a Distinct Molecular Landscape in Young-Onset Pancreatic Cancer.
Ogobuiro I; Baca Y; Ribeiro JR; Walker P; Wilson GC; Gulhati P; Marshall JL; Shroff RT; Spetzler D; Oberley MJ; Abbott DE; Kim HJ; Kooby DA; Maithel SK; Ahmad SA; Merchant NB; Xiu J; Hosein PJ; Datta J
JCO Precis Oncol; 2023 Sep; 7():e2300152. PubMed ID: 37944072
[TBL] [Abstract][Full Text] [Related]
2. Multi-omic characterization reveals a distinct molecular landscape in young-onset pancreatic cancer.
Ogobuiro I; Baca Y; Ribeiro JR; Walker P; Wilson GC; Gulhati P; Marshall JL; Shroff RT; Spetzler D; Oberley MJ; Abbott DE; Kim HJ; Kooby DA; Maithel SK; Ahmad SA; Merchant NB; Xiu J; Hosein PJ; Datta J
medRxiv; 2023 Mar; ():. PubMed ID: 37034762
[TBL] [Abstract][Full Text] [Related]
3. Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma.
Philip PA; Azar I; Xiu J; Hall MJ; Hendifar AE; Lou E; Hwang JJ; Gong J; Feldman R; Ellis M; Stafford P; Spetzler D; Khushman MM; Sohal D; Lockhart AC; Weinberg BA; El-Deiry WS; Marshall J; Shields AF; Korn WM
Clin Cancer Res; 2022 Jun; 28(12):2704-2714. PubMed ID: 35302596
[TBL] [Abstract][Full Text] [Related]
4. The genetic landscape of pancreatic head ductal adenocarcinoma in China and prognosis stratification.
Yang Y; Ding Y; Gong Y; Zhao S; Li M; Li X; Song G; Zhai B; Liu J; Shao Y; Zhu L; Pang J; Ma Y; Ou Q; Wu X; Zhang Z
BMC Cancer; 2022 Feb; 22(1):186. PubMed ID: 35180847
[TBL] [Abstract][Full Text] [Related]
5. Identification of Targetable Gene Fusions and Structural Rearrangements to Foster Precision Medicine in
Fusco MJ; Saeed-Vafa D; Carballido EM; Boyle TA; Malafa M; Blue KL; Teer JK; Walko CM; McLeod HL; Hicks JK; Extermann M; Fleming JB; Knepper TC; Kim DW
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250383
[TBL] [Abstract][Full Text] [Related]
6. Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4.
Masetti M; Acquaviva G; Visani M; Tallini G; Fornelli A; Ragazzi M; Vasuri F; Grifoni D; Di Giacomo S; Fiorino S; Lombardi R; Tuminati D; Ravaioli M; Fabbri C; Bacchi-Reggiani ML; Pession A; Jovine E; de Biase D
Cancer Biomark; 2018 Feb; 21(2):323-334. PubMed ID: 29103024
[TBL] [Abstract][Full Text] [Related]
7. Pathogenic genomic alterations in Chinese pancreatic cancer patients and their therapeutical implications.
Zhao Z; Li X; Wang F; Xu Y; Liu S; Han Q; Yang Z; Huang W; Yin Z; Liu Q; Tan H; Ma T; Si S; Huang J; Yuan H; Li W; Liu R
Cancer Med; 2023 May; 12(10):11672-11685. PubMed ID: 36999792
[TBL] [Abstract][Full Text] [Related]
8. KRAS mutation status is associated with specific pattern of genes expression in pancreatic adenocarcinoma.
Bittoni A; Piva F; Santoni M; Andrikou K; Conti A; Loretelli C; Mandolesi A; Lanese A; Pellei C; Scarpelli M; Principato G; Cascinu S
Future Oncol; 2015; 11(13):1905-17. PubMed ID: 26161927
[TBL] [Abstract][Full Text] [Related]
9. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma.
;
Cancer Cell; 2017 Aug; 32(2):185-203.e13. PubMed ID: 28810144
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer.
Singh H; Keller RB; Kapner KS; Dilly J; Raghavan S; Yuan C; Cohen EF; Tolstorukov M; Andrews E; Brais LK; da Silva A; Perez K; Rubinson DA; Surana R; Giannakis M; Ng K; Clancy TE; Yurgelun MB; Schlechter BL; Clark JW; Shapiro GI; Rosenthal MH; Hornick JL; Nardi V; Li YY; Gupta H; Cherniack AD; Meyerson M; Cleary JM; Nowak JA; Wolpin BM; Aguirre AJ
Clin Cancer Res; 2023 Nov; 29(22):4627-4643. PubMed ID: 37463056
[TBL] [Abstract][Full Text] [Related]
11. Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness.
Quintanilha JCF; Storandt MH; Graf RP; Li G; Keller R; Lin DI; Ross JS; Huang RSP; Schrock AB; Oxnard GR; Chakrabarti S; Mahipal A
JCO Precis Oncol; 2023 Jul; 7():e2300092. PubMed ID: 37410975
[TBL] [Abstract][Full Text] [Related]
12. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
Sinicrope FA; Shi Q; Smyrk TC; Thibodeau SN; Dienstmann R; Guinney J; Bot BM; Tejpar S; Delorenzi M; Goldberg RM; Mahoney M; Sargent DJ; Alberts SR
Gastroenterology; 2015 Jan; 148(1):88-99. PubMed ID: 25305506
[TBL] [Abstract][Full Text] [Related]
13. Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma.
McIntyre CA; Lawrence SA; Richards AL; Chou JF; Wong W; Capanu M; Berger MF; Donoghue MTA; Yu KH; Varghese AM; Kelsen DP; Park W; Balachandran VP; Kingham TP; D'Angelica MI; Drebin JA; Jarnagin WR; Iacobuzio-Donahue CA; Allen PJ; O'Reilly EM
Cancer; 2020 Sep; 126(17):3939-3949. PubMed ID: 32573775
[TBL] [Abstract][Full Text] [Related]
14. Precision medicine for KRAS wild-type pancreatic adenocarcinomas.
Ben-Ammar I; Rousseau A; Nicolle R; Tarabay A; Boige V; Valery M; Pudlarz T; Malka D; Gelli M; Fernandez-De-Sevilla E; Fuerea A; Tanguy ML; Rouleau E; Barbe R; Mathieu JRR; Jaulin F; Smolenschi C; Hollebecque A; Ducreux M; Boileve A
Eur J Cancer; 2024 Jan; 197():113497. PubMed ID: 38134480
[TBL] [Abstract][Full Text] [Related]
15. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma.
Qian ZR; Rubinson DA; Nowak JA; Morales-Oyarvide V; Dunne RF; Kozak MM; Welch MW; Brais LK; Da Silva A; Li T; Li W; Masuda A; Yang J; Shi Y; Gu M; Masugi Y; Bui J; Zellers CL; Yuan C; Babic A; Khalaf N; Aguirre A; Ng K; Miksad RA; Bullock AJ; Chang DT; Tseng JF; Clancy TE; Linehan DC; Findeis-Hosey JJ; Doyle LA; Thorner AR; Ducar M; Wollison B; Laing A; Hahn WC; Meyerson M; Fuchs CS; Ogino S; Hornick JL; Hezel AF; Koong AC; Wolpin BM
JAMA Oncol; 2018 Mar; 4(3):e173420. PubMed ID: 29098284
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic and prognostic associations of KRAS and BRAF mutations in small intestinal adenocarcinoma.
Jun SY; Kim M; Jin Gu M; Kyung Bae Y; Chang HK; Sun Jung E; Jang KT; Kim J; Yu E; Woon Eom D; Hong SM
Mod Pathol; 2016 Apr; 29(4):402-15. PubMed ID: 26892442
[TBL] [Abstract][Full Text] [Related]
17. Identification of the immune cell infiltration landscape in pancreatic cancer to assist immunotherapy.
Wang Z; Zou W; Wang F; Zhang G; Chen K; Hu M; Liu R
Future Oncol; 2021 Nov; 17(31):4131-4143. PubMed ID: 34346253
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic adenocarcinomas without KRAS, TP53, CDKN2A and SMAD4 mutations and CDKN2A/CDKN2B copy number alterations: a review of the genomic landscape to unveil therapeutic avenues.
Voutsadakis IA; Digklia A
Chin Clin Oncol; 2023 Feb; 12(1):2. PubMed ID: 36922358
[TBL] [Abstract][Full Text] [Related]
19. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.
Pai RK; Jayachandran P; Koong AC; Chang DT; Kwok S; Ma L; Arber DA; Balise RR; Tubbs RR; Shadrach B; Pai RK
Am J Surg Pathol; 2012 May; 36(5):744-52. PubMed ID: 22314188
[TBL] [Abstract][Full Text] [Related]
20. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer.
Yokose T; Kitago M; Matsuda S; Sasaki Y; Masugi Y; Nakamura Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Yusuke F; Nakano Y; Endo Y; Abe K; Tokino T; Kitagawa Y
Cancer Sci; 2020 Jun; 111(6):2174-2182. PubMed ID: 32314446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
